Norway-based Algeta has commenced a new oncology research programme to evaluate the potential of a targeted thorium conjugate (TTC).
The TTC is a combination of Algeta’s thorium-227 alpha-pharmaceutical payload and Immunomedics’ anti-CD22 monoclonal antibody (epratuzumab), a well-validated target for hematological cancers.
Go deeper with GlobalData
Algeta executive vice president and chief technology officer Thomas Ramdahl said thorium-227 payload has a broad utility and has better potential to kill cancer cells compared to other therapeutic payloads.
"This collaboration brings together Algeta, the global leader in alpha-pharmaceuticals and Immunomedics, a pioneer in antibody products and technologies," Ramdahl said.
"A TTC based on a well-validated antibody such as epratuzumab is an exciting prospect as we work to achieve our goal of generating a clinical candidate from the TTC platform in 2014."
According to the deal, Immunomedics will provide clinical-grade antibody to Algeta for the evaluation of potential of a TTC.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Algeta will fund all preclinical and clinical development expenses till the end of Phase I testing, after which the companies shall discuss licensing terms, based on certain parametres.
Immunomedics will earn a signature fee, an antibody delivery milestone and payments for cGMP antibody manufacture from Algeta in the first year.
Further details of the deal have not been revealed.
